enhance

The Christopher and Dana Reeve Foundation Expresses Disappointment Over President Bush's Veto of the Stem Cell Research Enhancement Act

SHORT HILLS, N.J., June 20, 2007 /PRNewswire-USNewswire/ -- TheChristopher and Dana Reeve Foundation (CDRF), the national,non-profit organization dedicated to finding cures and treatmentsfor spinal cord injuries and improving the lives of people livingwith paralysis, today expressed strong disappointment in PresidentBush's veto of the Stem Cell Research Enhancement Act, which wouldhave p...

Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting

SAN DIEGO--(BUSINESS WIRE)--Jun 6, 2007 - Inovio BiomedicalCorporation (AMEX:INO), focused on the development of DNA vaccinesfor cancers and infectious diseases and a novel alternative tosurgery to treat localized cancers, announced today the companydelivered multiple presentations on preclinical study results andnew device innovations relating to its electroporation-mediated DNAdelivery te...

Biothera's Imprime PGG Enhanced Effectiveness of Avastin in Cancer Study

EAGAN, Minn.--(BUSINESS WIRE)--Jun 4, 2007 - Imprime PGG(TM), aninvestigational new drug from Biothera that enhances the innateimmune system response, increases the effectiveness of Avastin(R)(bevacizumab) to kill cancer cells, according to new preclinicalresearch presented yesterday at the 2007 American Society ofClinical Oncology Annual Meeting in Chicago. Researchers at the Brown Cance...

Inovio Biomedical's DNA Delivery Technology Shows Safety and Enhances Gene Expression & Tumor Responses in Interim Melanoma Clinical Study Results

SAN DIEGO--(BUSINESS WIRE)--May 24, 2007 - Inovio BiomedicalCorporation (AMEX:INO), focused on the development of DNA-based DNAvaccines for cancers and infectious diseases and a novelalternative to surgery to treat localized cancers, announced todaythat interim clinical trial results demonstrated that a DNA-basedimmunotherapy delivered by Inovio's electroporation technology wassafe and tole...

CEL-SCI'S CEL-1000 Shown to Significantly Enhance Immune Response Against Avian Flu Antigen in Animals

VIENNA, Va., May 23, 2007 /PRNewswire-FirstCall/ -- CEL-SCICORPORATION announces that CEL-1000 increased the immune responseagainst H5 avian influenza antigen in combination with MAS-1, awater-in-oil adjuvant delivery system. These findings werepresented on May 23, 2007 by Dr. Daniel Zimmerman, Senior VicePresident of Research, Cellular Immunology at CEL-SCI at theAmerican Society of Mic...

Vical's Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues

MALAGA, Spain, May 23, 2007 /PRNewswire-FirstCall/ -- VicalIncorporated today announced that in a recently completed animalstudy, a DNA vaccine formulated with the company's patentedVaxfectin(TM) adjuvant and delivered by needle-free injectionyielded significantly higher antibody responses than anunformulated DNA vaccine delivered by needle and syringe. In aseparate animal study, electro...

CEL-SCI's Cel-1000 Shown to Significantly Enhance Immune Response Against Hepatitis B Antigen in Animals

VIENNA, Va., May 01, 2007 /PRNewswire-FirstCall/ -- CEL-SCICORPORATION announces that CEL-1000 alone increased the immuneresponse against hepatitis B antigen, and that the combination ofCEL-1000 with MAS-1, a proprietary water-in-oil adjuvant deliverysystem owned by Mercia Pharma, induced highly significant increasesin specific anti-HBV (hepatitis B virus) antibodies. These findingswere...

Favrille Announces Results From Study Showing Enhanced Activity From Insect Cell-Derived Immunotherapy for Lymphoma

Data Reported at American Association for Cancer Research AnnualMeeting SAN DIEGO, April 18, 2007 /PRNewswire-FirstCall/ -- Favrille,Inc. , a biopharmaceutical company developing patient-specific,active immunotherapies for the treatment of cancer, announcedresults from a new study showing enhanced activity from insect-cellderived idiotype (Id) proteins, a key component in the Company'sId...

Inovio Biomedical's DNA Delivery Technology Significantly Enhances Potency of HIV DNA Vaccine

SAN DIEGO--(BUSINESS WIRE)--Mar 26, 2007 - Inovio Biomedical Corp.(AMEX:INO), which is focused on the development of DNA vaccines anda novel solid tumor ablation therapy, announced today that theJournal of Virology has published a scientific paper prepared byInovio's development partner, Wyeth, regarding results from anon-human primate study of an investigational DNA vaccine againstHIV deli...

Studies Show Mild Hyperthermia Enhances Antitumor Effects of Alfacell's Onconase

BLOOMFIELD, N.J., March 22, 2007 /PRNewswire-FirstCall/ --Alfacell Corporation today reported that in vitro studies show mildhyperthermia enhances the therapeutic effects of ONCONASE(ranpirnase), the company's lead investigational drugcandidate. In a paper entitled, "Mild hyperthermia predisposes tumor cellsto undergo apoptosis upon treatment with ONCONASE," published inthe Intern...